Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC

Annals of Oncology

Volumn 15, Issue 3, 2004, Pages 410-418

  Rocha Lima, C M S ^a   Rizvi, N A ^b   Zhang, C ^c   Herndon, II ^b   Crawford, J ^d   Govindan, R ^e   King, G W ^f   Green, M R ^g  

^a UNIVERSITY OF MIAMI   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c CALGB Statistical Center   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Cancer Centers of the Carolinas   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

CALGB 39809; Docetaxel; Gemcitabine; Irinotecan; Non small cell lung cancer

Indexed keywords

DOCETAXEL; GEMCITABINE; IRINOTECAN; POTASSIUM; SODIUM;

ADULT; AGED; ANEMIA; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HYPOKALEMIA; HYPONATREMIA; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 1842555352     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh104     Document Type: Article

References (49)

1. National Cancer Institute. Non-small cell lung cancer (PDQ®). [On-line] http://cancernet.nci.nih.gov (20 September 2002, date last accessed).
2. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997; 15: 2996-3018.
3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311: 899-909.
4. Ranson M, Davidson N, Nicolson M et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92: 1074-1080.
5. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
6. Wozniak AJ, Crowley JJ, Balcerzak SP et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 1998; 16: 2459-2465.
7. Sandler AB, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18: 122-130.
8. Bonomi P, Kim Y, Fairclough D et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18: 623-631.
9. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
10. Perry MC, Ihde DC, Herndon JE 2nd et al. Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. Lung Cancer 2000; 28: 63-68.
11. Anderson H, Lund B, Bach F et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1994; 12: 1821-1826.
12. Abratt RP, Bezwoda WR, Falkson G et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 1994; 12: 1535-1540.
13. Gatzemeier U, Shepherd FA, Le Chevalier T et al. Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study. Eur J Cancer 1996; 32A: 243-248.
14. Burris H, Eckardt J, Fields S et al. Phase II trials of Taxotere in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 1993; 12: 335 (Abstr 1116).
15. Cerny T, Kaplan S, Pavlidis N et al. Docetaxel (Taxotere™) is active in non-small-cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 1994; 70: 384-387.
16. Fossella FV, Lee JS, Shin DM et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995; 13: 645-651.
17. Fossella FV, Lee JS, Berille J, Hong WK. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer. Semin Oncol 1995; 22 (Suppl 4): 22-29.
18. Francis PA, Rigas JR, Kris MG et al. Phase R trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994; 12: 1232-1237.
19. Baker L, Khan R, Lynch T et al. Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1997; 16:461a (Abstr 1658).
20. Douillard JY, Ibrahim N, Rivière A et al. Phase II study of CPT-11 (irinotecan) in non small cell lung cancer. Proc Am Soc Clin Oncol 1995; 14: 365 (Abstr 1118).
21. Fukuoka M, Niitani H, Suzuki A et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992; 10: 16-20.
22. Negoro S, Fukuoka M, Masuda N et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991; 83: 1164-1168.
23. Bhargava P, Marshall JL, Fried K et al. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer. Cancer Chemother Pharmacol 2001; 48: 95-103.
24. Rizvi NA, Marshall J, Dahut W, Hawkins MJ. Phase I dose escalation and sequencing study of gemcitabine and docetaxel in advanced cancers. Ann Oncol 1998; 9 (Suppl 4): 131 (Abstr 629P).
25. Rocha Lima CMS, Leong SS, Sherman C et al. Phase I study of CPT-11 and gemcitabine in patients with solid tumors. Cancer Ther 1999; 2: 58-66.
26. Bahadori HR, Rocha Lima CMS, Green MR, Safa AR. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res 1999; 19: 5423-5428.
27. Kanzawa F, Saijo N. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol 1997; 24 (Suppl 7): 8-16.
28. Amenedo M, Mel JR, Huidobro G et al. Phase II multicenter clinical trial of gemcitabine (G) and docetaxel (D) in advanced non-small-cell lung cancer (NSCLC): Final results. Proc Am Soc Clin Oncol 2001; 20: 265b (Abstr 2813).
29. Georgoulias V, Kouroussis C, Androulakis N et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial. J Clin Oncol 1999; 17: 914-920.
30. Hejna M, Kornek GV, Raderer M et al. Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor. Cancer 2000; 89: 516-522.
31. Lizon J, Feliu J, Morales S et al. A phase II study of gemcitabine plus docetaxel as first line treatment in non-small-cell lung cancer. an Oncopaz and Associated Hospitals study. Proc Am Soc Clin Oncol 2001; 20: 270b (Abstr 2833).
32. McKay C 3rd, Hainsworth J, Burris H 3rd et al. Weekly docetaxel/gemcitabine in the treatment of elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): A Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 2001; 20: 260b (Abstr 2793).
33. Neubauer M, Garfield D, Khan M et al. Phase-II trial of weekly DOCETAXEL (Taxotere) plus GEMCITABINE (Gemzar) as first-line therapy for patients (pts) with advanced non-small cell lung cancer (ANSCLC). Proc Am Soc Clin Oncol 2001; 20: 252b (Abstr 2760).
34. Menendez P, Gomez RG, Mendez M et al. A phase II study of a combination of docetaxel and gemcitabine in a weekly schedule as first line treatment in stages IIIB/IV non-small-cell lung cancer (NSCLC). Goti Study Group. Proc Am Soc Clin Oncol 2001; 20: 256b (Abstr 2777).
35. Popa IE, Stewart K, Smith FP, Rizvi NA. A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naïve, advanced nonsmall cell lung carcinoma. Cancer 2002; 15: 1714-1719.
36. Rebattu P, Quantin X, Ardiet C et al. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer 2001; 33: 277-287.
37. Syrigos KN, Dionellis G, Alevyzaki F et al. Biweekly administration of docetaxel (DOC) and gemcitabine (GEM) in patients (pts) with non-small cell lung cancer (NSCLC): A phase II study. Proc Am Soc Clin Oncol 2001; 20: 260b (Abstr 2791).
38. Ventriglia M, Estevez R, Cabrera L et al. A phase II study of gemcitabine (G) plus docetaxel (D) as first line chemotherapy for advanced NSCLC patients (PTS). Lung Cancer 2000; 29 (Suppl 1): 70 (Abstr 226).
39. Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial. Lancet 2001; 357: 1478-1484.
40. Kakolyris SS, Kouroussis C, Koukourakis M et al. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy. Anticancer Res 2002; 22: 1891-1896.
41. Nishio M, Oyanagi F, Karato A et al. Phase I study of biweekly chemotherapy with gemcitabine (GEM) and irinotecan (CPT-11) in previously treated patients (pts) with non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21: 219b (Abstr 2693).
42. Kouroussis C, Agelidou A, Apostolopoulou F et al. Second-line treatment with irinotecan (CPT-11) and gemcitabine (GEM) versus CPT-11 in patients with advanced NSCLC pretreated with taxanes and cisplatinum: preliminary results of a multicenter randomized phase II study. Proc Am Soc Clin Oncol 2002; 21: 304a (Abstr 1212).
43. Carmichael J, Possinger K, Phillip P et al. Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731-2736.
44. Dunsford ML, Mead GM, Bateman AC et al. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 1999; 10: 943-947.
45. Etienne B, Perol M, Nesme P et al. Acute diffuse interstitial pneumopathy following docetaxel (Taxotere). Apropos of 2 cases. Rev Mal Respir 1998; 15: 199-203.
46. Merad M, Le Cesne A, Baldeyrou P et al. Docetaxel and interstitial pulmonary injury. Ann Oncol 1997; 8: 191-194.
47. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286-291.
48. Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002; 94: 847-853.
49. Giaccone G on behalf of the European Organization for Research and Treatment of Cancer Group. Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975. Semin Oncol 2002; 29 (Suppl 9): 47-49.